Not all acute coronary syndrome patients get appropriate tx

Not all acute coronary syndrome patients get appropriate tx
Nearly one in five eligible patients hospitalized for acute coronary syndrome do not receive American College of Cardiology/American Heart Association class I guideline-recommended angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, according to a study published online Feb. 25 in Circulation: Cardiovascular Quality and Outcomes.

(HealthDay)—Nearly one in five eligible patients hospitalized for acute coronary syndrome do not receive American College of Cardiology/American Heart Association (ACC/AHA) class I guideline-recommended angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, according to a study published online Feb. 25 in Circulation: Cardiovascular Quality and Outcomes.

Kevin R. Bainey, M.D., from the University of Alberta in Edmonton, Canada, and colleagues examined the extent to which ACEI/ARB therapy is applied in patients with . Data were collected from 80,241 patients admitted with an acute coronary syndrome and discharged home from 311 U.S. hospitals participating in the Get With the Guidelines-Coronary Artery Disease Program (January 2005 to December 2009).

The researchers found that 81 percent of the 60,847 patients with an ACC/AHA class I indication (left ventricular dysfunction or medical history of heart failure, hypertension, diabetes mellitus, or ) received ACEI/ARB. The rate of treatment increased over the study period (76.7 to 84.6 percent; adjusted odds ratio [OR], 1.17; P < 0.001, per calendar year). There were independent associations between in-hospital coronary bypass grafting (adjusted OR, 0.55) and renal insufficiency (adjusted OR, 0.58) with lower usage.

"These findings highlight an unmet need in this population and provide an incentive for additional quality improvement efforts," the authors write.

The Get With the Guidelines-Coronary Artery Disease Program is supported in part by Merck/Schering-Plough and Pfizer. Several authors disclosed financial ties to the medical device and pharmaceutical industries.

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2014 HealthDay. All rights reserved.

Citation: Not all acute coronary syndrome patients get appropriate tx (2014, February 26) retrieved 28 March 2024 from https://medicalxpress.com/news/2014-02-acute-coronary-syndrome-patients-tx.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Antihypertensives associated with lower dialysis risk for patients with advanced CKD

0 shares

Feedback to editors